Please, the approval is not conditional. Do your DD.
The studies Epicept will implement this fall shall be seen as a new source of HOW Ceplene is working.
The results do not, by any means, have something to do with the indreasing sales from now on. Just read the documents from EU. It's all there.
By the way. Ceplene IS in the market through the IDIS agreement. For the whole world, but the US market. There have not yet been published any sales figures from this. That will be reported in November in the Q3 report.